ES2188426A1 - Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. - Google Patents

Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.

Info

Publication number
ES2188426A1
ES2188426A1 ES200102836A ES200102836A ES2188426A1 ES 2188426 A1 ES2188426 A1 ES 2188426A1 ES 200102836 A ES200102836 A ES 200102836A ES 200102836 A ES200102836 A ES 200102836A ES 2188426 A1 ES2188426 A1 ES 2188426A1
Authority
ES
Spain
Prior art keywords
psoriasis
treatment
denotes
pharmaceutical composition
skin diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200102836A
Other languages
English (en)
Other versions
ES2188426B1 (es
Inventor
Fernandez Rosalia Pidal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200102836A priority Critical patent/ES2188426B1/es
Application filed by Individual filed Critical Individual
Priority to PT02796785T priority patent/PT1473300E/pt
Priority to DE60230066T priority patent/DE60230066D1/de
Priority to AT02796785T priority patent/ATE415410T1/de
Priority to AU2002361265A priority patent/AU2002361265A1/en
Priority to PCT/ES2002/000591 priority patent/WO2003053991A1/es
Priority to EP02796785A priority patent/EP1473300B1/en
Priority to JP2003554707A priority patent/JP2005513139A/ja
Priority to CA002470364A priority patent/CA2470364A1/en
Priority to ES02796785T priority patent/ES2318061T3/es
Publication of ES2188426A1 publication Critical patent/ES2188426A1/es
Priority to US10/865,991 priority patent/US20040225140A1/en
Application granted granted Critical
Publication of ES2188426B1 publication Critical patent/ES2188426B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición farmacéutica para el tratamiento de la psoriasis y otras dermopatías. Comprende 17-propionato de clobetasol, 11alfa- hidroxiprogesterona (o alternativamente 11 alfa- acetoxiprogesterona) y cantidades adecuadas de excipientes para constituir una formulación tópica. Preferiblemente se administra como loción con: 0,05-0,2% de 17-propionato de clobetasol; 0,3-1% de 11alfa-hidroxiprogesterona; un disolvente seleccionado entre etanol, isopropanol y sus mezclas; un 40% de codisolvente seleccionado entre propilenglicol, glicerina, sorbitol y sus mezclas; y un 20% de agua. Es especialmente preferida la loción donde el disolvente es etanol, y los codisolventes son aproximadamente: 35% de propilenglicol, 5% de glicerina y 20% de agua. Respecto a los tratamientos conocidos con corticoides tópicos, la composición de la invención presenta las ventajas de una recidiva mucho más espaciada y de muchos menos efectos secundarios locales. La composición es útil para el tratamiento de la psoriasis.
ES200102836A 2001-12-12 2001-12-12 Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. Expired - Lifetime ES2188426B1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ES200102836A ES2188426B1 (es) 2001-12-12 2001-12-12 Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
CA002470364A CA2470364A1 (en) 2001-12-12 2002-12-11 Pharmaceutical composition for the treatment of psoriasis and other skin diseases
AT02796785T ATE415410T1 (de) 2001-12-12 2002-12-11 Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheiten
AU2002361265A AU2002361265A1 (en) 2001-12-12 2002-12-11 Pharmaceutical composition for the treatment of psoriasis and other skin diseases
PCT/ES2002/000591 WO2003053991A1 (es) 2001-12-12 2002-12-11 Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias
EP02796785A EP1473300B1 (en) 2001-12-12 2002-12-11 Pharmaceutical composition for the treatment of psoriasis and other skin diseases
PT02796785T PT1473300E (pt) 2001-12-12 2002-12-11 Composição farmacêutica para o tratamento de psoríase e outras doenças de pele
DE60230066T DE60230066D1 (de) 2001-12-12 2002-12-11 Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheiten
ES02796785T ES2318061T3 (es) 2001-12-12 2002-12-11 Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
JP2003554707A JP2005513139A (ja) 2001-12-12 2002-12-11 乾癬及び他の皮膚疾患の治療のための製薬組成物
US10/865,991 US20040225140A1 (en) 2001-12-12 2004-06-11 Pharmaceutical composition for the treatment of psoriasis and other skin diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200102836A ES2188426B1 (es) 2001-12-12 2001-12-12 Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.

Publications (2)

Publication Number Publication Date
ES2188426A1 true ES2188426A1 (es) 2003-06-16
ES2188426B1 ES2188426B1 (es) 2004-11-16

Family

ID=8499799

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200102836A Expired - Lifetime ES2188426B1 (es) 2001-12-12 2001-12-12 Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
ES02796785T Expired - Lifetime ES2318061T3 (es) 2001-12-12 2002-12-11 Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02796785T Expired - Lifetime ES2318061T3 (es) 2001-12-12 2002-12-11 Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.

Country Status (10)

Country Link
US (1) US20040225140A1 (es)
EP (1) EP1473300B1 (es)
JP (1) JP2005513139A (es)
AT (1) ATE415410T1 (es)
AU (1) AU2002361265A1 (es)
CA (1) CA2470364A1 (es)
DE (1) DE60230066D1 (es)
ES (2) ES2188426B1 (es)
PT (1) PT1473300E (es)
WO (1) WO2003053991A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2070533A1 (en) 2007-12-11 2009-06-17 Apoteknos Para La Piel, s.l. Use of a compound derived from P-hydroxyphenyl propionic acid for the treatment of psoriasis

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2898499B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
FR2898498B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
ES2288133B1 (es) 2006-06-12 2008-09-16 Maria Cristina Fernandez Rodriguez Composicion topica para el tratamiento de la psoriasis.
ES2334381T3 (es) * 2006-08-17 2010-03-09 Klever Mode, S.L. Formulacion farmaceutica para el tratamiento de afecciones en la piel.
WO2012129305A1 (en) * 2011-03-23 2012-09-27 Pop Test Cortisol Llc Combination therapy
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017037663A1 (en) 2015-09-02 2017-03-09 Cadila Healthcare Limited Topical compositions comprising corticosteroids
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998036753A1 (en) * 1997-02-20 1998-08-27 Allergan Sales,Inc. Tazarotene and corticosteroid treatment for psoriasis
US5972920A (en) * 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966924A (en) * 1974-11-13 1976-06-29 Allergan Pharmaceuticals Composition and method for treating psoriasis
JPS56135416A (en) * 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
EP0625045A4 (en) * 1992-02-07 1995-01-18 Albert M Kligman METHOD FOR TREATING FLAMMABLE DERMATOS.
WO1994013257A1 (en) * 1992-12-16 1994-06-23 Creative Products Resource Associates, Ltd. Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998036753A1 (en) * 1997-02-20 1998-08-27 Allergan Sales,Inc. Tazarotene and corticosteroid treatment for psoriasis
US5972920A (en) * 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARAN, R. et al.: "Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation". J. of Dermatological Treatment, 1999, Volumen 10, pßginas 201-204, todo el documento. *
SWINKELS, O.Q.J. et al.: "The influence of a topical corticosteroid on short-contact high-dose dithranol therapy". British J. of Dermatology, 2001, Volumen 145, pßginas 63-69, todo el documento. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2070533A1 (en) 2007-12-11 2009-06-17 Apoteknos Para La Piel, s.l. Use of a compound derived from P-hydroxyphenyl propionic acid for the treatment of psoriasis

Also Published As

Publication number Publication date
PT1473300E (pt) 2009-02-27
ES2318061T3 (es) 2009-05-01
JP2005513139A (ja) 2005-05-12
AU2002361265A1 (en) 2003-07-09
ES2188426B1 (es) 2004-11-16
EP1473300B1 (en) 2008-11-26
ATE415410T1 (de) 2008-12-15
DE60230066D1 (de) 2009-01-08
CA2470364A1 (en) 2003-07-03
EP1473300A1 (en) 2004-11-03
US20040225140A1 (en) 2004-11-11
WO2003053991A1 (es) 2003-07-03

Similar Documents

Publication Publication Date Title
AU2002361265A1 (en) Pharmaceutical composition for the treatment of psoriasis and other skin diseases
MY119181A (en) Aryl pyrimidine derivatives
ATE252529T1 (de) Colchinolderivate als gefässschädigende mittel
WO2002022598A8 (en) Quinolinone derivatives as tyrosine kinase inhibitors
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
BR9909796B1 (pt) "derivados de piperidinopirimidina para aplicação tópica"
WO2005011653A3 (en) Pyridazine derivatives and their use as therapeutic agents
PT1227820E (pt) Acidos oligossacarido-aldonicos e sua utilizacao topica
DK1392329T3 (da) Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
MXPA02006150A (es) Formulaciones de liberacion sostenida de un inhibidor de ciclooxigenasa-2.
TR199802060T2 (xx) Aminoisokinolinler ve aminopiridin t�revlerinin iltihap �nleyiciler olarak kullan�m�.
BR0109515A (pt) Derivados da apomorfina e métodos para seu uso
JPH0662390B2 (ja) ラクタムを含有する化粧品組成物
JPH0517365A (ja) テストステロン ５α−レダクターゼ阻害剤
RU2153874C2 (ru) Применение 2,4-диаминопиримидин-3-оксида или одной из его солей при лечении нарушений формирования и структурирования коллагена
WO2002047673A3 (en) Methods and compositions to treat conditions associated with neovascularization
CA2378834A1 (en) Pyrazinones, compositions containing such compounds
WO2001074807A1 (en) Indolylpyrrole derivatives and cell death inhibitors
JPH06502161A (ja) レチノイド浸透作用エンハンサーを含む局所用組成物
TW200501995A (en) Treatment for skin
JP2008539236A5 (es)
DK1194109T3 (da) Topiske formuleringer omfattende hud-gennemtrængningsmidler samt anvendelse deraf
JP2000229857A (ja) テストステロン−５α−レダクターゼ阻害剤
AP9801235A0 (en) Erythromycin derivatives.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030616

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2188426B1

Country of ref document: ES

FA2A Application withdrawn

Effective date: 20050401